Welcome to the CMC Strategy Forum Europe 2017
|
|
- Felix Barton
- 6 years ago
- Views:
Transcription
1 Welcome to the CMC Strategy Forum Europe 2017 The 11 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and manufacturing of biopharmaceutical products. A series of plenary sessions and workshops led by experts from global regulatory agencies, academia and industry seek to explore emerging aspects of CMC technology and regulation in areas where existing modalities and systems are undergoing change. Topics will include: Regulatory Update from Around the World; The Continuing Evolution of Product Characterization; Manufacturing Process Development and Control Strategies; Statistical Tools to Evaluate Quality Attributes for Comparability and Biosimilarity; and Opportunities and Obstacles for Accelerated CMC Development. The EBE session will present updates on the following concept papers: A Risk-based Approach to Setting Sterile Filtration Bioburden Limits; A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-derived Injectable Drug Products; and Drug Device Combination Products, as well as the workshop topic: ATMPs Specific Challenges in Development and Commercialization. The CMC Strategy Forum is designed to maximize dialog between participants. Presentations are relatively short and focused and set the agenda for the panel discussions to engage all the participants who have experience and expertise to share. It should be important for you to attend this event as we come together to discuss important issues on how to ensure product safety and efficacy for the patients we serve. We would like to thank the speakers and panel members who are giving generously of their time and resources, and to you, for your attendance. We acknowledge the generosity of our program partners: AbbVie, Inc.; Amgen Inc.; Biogen, Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann- La Roche Ltd.; IPSEN Biopharm Ltd.; MedImmune, A member of the AstraZeneca Group; Merck & Co., Inc.; Novo Nordisk A/S and Pfizer, Inc. We are grateful for the expert management from CASSS and the audio-visual expertise of Michael Johnston from MJ Audio-Visual Productions. Their experience and guidance in the preparation of this Forum has been invaluable.
2 ACKNOWLEDGEMENTS CMC STRATEGY FORM EUROPE PROGRAM COMMITTEE Sandra Patricia Auguste-Bowler, LEO Pharma A/S, Denmark Seán Barry, Health Products Regulatory Authority (HPRA), Ireland (Co-chair) Brigitte Brake, Federal Institute for Drugs and Medical Devices (BfArM), Germany Emmanuelle Charton, EDQM, Council of Europe, France Niklas Ekman, Finnish Medicines Agency, Finland Chana Fuchs, CDER, FDA, USA Ralf Gleixner, Merck Serono, Switzerland Jason Hampson, Amgen Inc., USA Kowid Ho, F. Hoffmann-La Roche Ltd., Switzerland (Co-chair) Brendan Hughes, Bristol-Myers Squibb Company, USA Ronald Imhoff, Janssen Biologics BV, Netherlands Alistair Kippen, IPSEN Biopharm Ltd., United Kingdom (Co-chair) Ingrid Markovic, CBER, FDA, USA Jens Bjørn Nielsen, Novo Nordisk A/S, Denmark Fionnuala O Driscoll, Eli Lilly SA Irish Branch, Ireland Bridgett O Shea, Pfizer Ireland Pharmaceuticals Limited, Ireland Ilona Reischl, Austrian Agency for Health and Food Safety (AGES), Austria Mark Schenerman, MedImmune, A member of the AstraZeneca Group, USA Martin Schiestl, Sandoz Biopharmaceuticals, Austria Thomas Schreitmüller, F. Hoffmann-La Roche Ltd., Switzerland Jolanda Westerlaken, UCB Pharma sprl, Canada CMC STRATEGY FORUM GLOBAL STEERING COMMITTEE Siddharth Advant, Celgene Corporation, USA Daniela Cerqueria, ANVISA-Brasilian National Health Surveillance Agency, Brasil Yasuhiro Kishioka, PMDA-Pharmaceutical and Medical Devices Agency, Japan Steven Kozlowski, CDER, FDA, USA Junichi Koga, Daiichi Sankyo Co., Ltd., Japan Rohin Mhatre, Biogen, USA Anthony Mire-Sluis, AstraZeneca., USA Wassim Nashabeh, F. Hoffmann-La Roche Ltd., Switzerland (Chair) Ilona Reischl, AGES-Austrian Agency for Health and Food Safety, Austria Anthony Ridgway, Health Canada, Canada Nadine Ritter, Global Biotech Experts, LLC, USA Thomas Schreitmüller, F. Hoffmann-La Roche Ltd., Switzerland Mark Schenerman, MedImmune, A member of the AstraZeneca Group, USA Karin Sewerin, BioTech Development AB, Sweden
3 The Scientific Organizing Committee gratefully acknowledges the program partners for their generous support of the CMC Strategy Forum Europe STRATEGIC DIAMOND PROGRAM PARTNER F. Hoffmann-La Roche Ltd. STRATEGIC PLATINUM PROGRAM PARTNERS AbbVie, Inc. Biogen MedImmune, A member of the AstraZeneca Group STRATEGIC GOLD PROGRAM PARTNERS Eli Lilly and Company Pfizer, Inc. STRATEGIC SILVER PROGRAM PARTNER Merck & Co., Inc. SILVER PROGRAM PARTNERS Amgen Inc. Bristol-Myers Squibb Company BRONZE PROGRAM PARTNER IPSEN Biopharm Ltd. FRIEND of CASSS PROGRAM PARTNER Novo Nordisk A/S
4 The Scientific Organizing Committee gratefully acknowledges the following media for their promotional consideration of the CMC Strategy Forum Europe series. LEADING MEDIA PARTNERS BioProcess International International Pharmaceutical Quality MEDIA PARTNERS American Laboratory / LabCompare American Pharmaceutical Review BioPharm International BioProcessing Journal Genetic Engineering & Biotechnology News G.I.T. Laboratory Journal LC/GC Europe Pharmaceutical Outsourcing Royal Society of Chemistry separationsnow.com Technology Networks
5 European Biopharmaceutical Enterprises (EBE) Satellite Session Monday, 22 May :30 08:30 Breakfast in the Garden Room Restaurant (Breakfast is included in the CMC Strategy Forum group sleeping room rate; other attendees / guests can pay individually for breakfast if they are not included in the group room rate) 07:30 12:00 Registration in the Muckross Suite Foyer 08:30 08:45 Welcome and Introduction to the European Biopharmaceutical Enterprises (EBE) Ongoing Activities and Initiatives in the Muckross Suite Markus Goese, F. Hoffmann-La Roche Ltd., Switzerland Concept Paper 2017 Update: New Initiatives In the Muckross Suite Session Chairs: Ronald Imhoff, Janssen Biologics BV and Fionnuala O Driscoll, Eli Lilly S.A. Irish Branch 08:45 09:00 Risk-based Approaches regarding Bioburden Sampling and Limits on ID Sampling of Biologics API Karoline Bechtold Peters, Novartis Pharmaceuticals Corporation, Switzerland 09:00 09:15 A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-derived Injectable Drug Products Tapan Das, Bristol-Myers Squibb Company, USA 09:15 09:30 Drug Device Combination Products Serge Mathonet, Sanofi, France 09:30 10:00 Panel Discussion Questions and Answers 10:00 10:30 Networking Break in the Muckross Suite Foyer ATMP - Specific Challenges in Development and Commercialization Workshop In the Muckross Suite Session Chairs: Ronald Imhoff, Janssen Biologics BV and Fionnuala O Driscoll, Eli Lilly S.A. Irish Branch 10:30 10:45 EU Regulatory Activities for ATMPs Ilona Reischl, AGES-Austrian Agency for Health and Food Safety, Austria 10:45 11:00 Critical Quality Attributes for C> Products Enabling Comparability Assessments through Product Development Ben Thompson, GlaxoSmithKline, United Kingdom
6 Monday, 22 May continued 11:00 11:15 The Imlygic Story: A Winding Road to Innovation Michael Abernathy, Amgen Inc., USA 11:15 11:30 A Living Medicine: How to Cope with CMC Requirements in the Development of Cell Therapy Products of Autologous and Allogeneic Origin Wilfried Dalemans, TiGenix, Belgium 11:30 12:00 Panel Discussion Questions and Answers 12:00 12:15 Concluding Remarks Veronique Debaut, European Biopharmaceutical Enterprises (EBE), Belgium
7 Monday, 22 May continued CMC Strategy Forum Europe 2017 Scientific Program Summary 12:15 14:00 Buffet Lunch in the Garden Room Restaurant 13:15 17:00 Registration in the Muckross Suite Foyer 14:00 14:15 CASSS Welcome and Introductory Comments in the Muckross Suite Wassim Nashabeh, F. Hoffmann-La Roche Ltd., Switzerland Introduction / Welcome to the 11 th European CMC Strategy Forum Alistair Kippen, IPSEN Biopharm Ltd. Regulatory Updates from Around the World Plenary Session in the Muckross Suite Session Chairs: Kowid Ho, F. Hoffmann-La Roche Ltd. and Alistair Kippen, IPSEN Biopharm Ltd. 14:15 14:45 Biopharmaceuticals A Regulatory Perspective Maeve Lally, Health Products Regulatory Authority (HPRA), Ireland 14:45 15:15 EU Update on Regulatory Developments Pascal Venneugues, European Medicines Agency (EMA), United Kingdom 15:15 15:45 Regulation of Biological Products in Ghana and the Economic Community of West African States (ECOWAS) Region Eric Karikari-Boateng, Foods and Drug Authority, Ghana 15:45 16:15 Networking Break in the Muckross Suite Foyer 16:15 16:45 TBD Chana Fuchs, CDER, FDA, USA 16:45 18:00 Panel Discussion Questions and Answers Chana Fuchs, CDER, FDA, USA Eric Karikari-Boateng, Foods and Drug Authority, Ghana Maeve Lally, Health Products Regulatory Authority (HPRA), Ireland Patrick Owusu-Danso, Foods and Drug Authority, Ghana Pascal Venneugues, European Medicines Agency (EMA), United Kingdom
8 Monday, 22 May continued 18:00 19:00 Welcome Reception in the Malton Gardens 19:00 Adjourn Day One
9 Tuesday, 23 May :30 08:45 Breakfast in the Garden Room Restaurant (Breakfast is included in the CMC Strategy Forum group sleeping room rate; other attendees / guests can pay individually for breakfast if they are not included in the group room rate) 08:00 17:00 Registration in the Muckross Suite Foyer The Continuing Evolution of Product Characterization Workshop Session One in the Forum Rooms E-J Session Chairs: Brendan Hughes, Bristol-Myers Squibb Company and Mark Schenerman, MedImmune, A member of the AstraZeneca Group 09:00 09:10 Introduction 09:15 09:40 Technical Innovations Impact on Regulatory Expectations for Product Characterization Steffen Gross, Paul-Ehrlich-Institut, Germany 09:40 10:05 Analytical Control Strategy for Co-formulated Biologics Product Amit Katiyar, Bristol-Myers Squibb Company, USA 10:05 10:30 Review of Activity Testing for Pfizer Biologic Molecule Brian Hassett, Pfizer Ireland Pharmaceuticals, Ireland 10:30 10:55 Analytical Characterization of Biologic-Biologic Combinations Methal Albarghouthi, MedImmune, A member of the AstraZeneca Group, USA 11:00 11:30 Networking Break in the Muckross Suite Foyer 11:30 12:30 Panel Discussion Questions and Answers Methal Albarghouthi, MedImmune, A member of the AstraZeneca Group, USA Emmanuelle Charton, EDQM, Council of Europe, France Steffen Gross, Paul-Ehrlich-Institut, Germany Brian Hassett, Pfizer Ireland Pharmaceuticals, Ireland Amit Katiyar, Bristol-Myers Squibb Company, USA 12:30 14:00 Buffet Lunch in the Garden Room Restaurant
10 Tuesday, 23 May continued Manufacturing Process Development and Control Strategies Workshop Session Two in the Muckross Suite Session Chairs: Ralf Gleixner, Merck Serono and Ronald Imhoff, Janssen Biologics B.V. 14:00 14:10 Introduction 14:15 14:40 Approvable Process Control Scientific Thinking above Creative Marketing Amanda Shipman, MHRA-Medicines and Healthcare Products Regulatory Agency, United Kingdom 14:40 15:05 Use of Quality by Design principles for Developmennt of an Integrated Control Strategy Girish Pendse, Eli Lilly and Company, USA 15:05 15:30 Analytical Control Strategies: From Molecular Understanding to CQAs, Specifications and Lifecycle Management Garry Takle, Merck, Sharp & Dohme, USA 15:30 15:55 Implementation of an Online UV Monitoring System in Tinzaparin Sodium: A Case Study in Approaches to Manufacturing Development and Strategies to Improve Efficiencies with Regulatory Robert Kelly, LEO Pharma, Ireland 16:00 16:30 Networking Break in the Muckross Suite Foyer 16:30 17:30 Panel Discussion Questions and Answers Chana Fuchs, CDER, FDA, USA Robert Kelly, LEO Pharma, Ireland Greg Naugle, Amgen Inc., USA Girish Pendse, Eli Lilly and Company, USA Amanda Shipman, MHRA-Medicines and Healthcare Products Regulatory Agency, United Kingdom Garry Takle, Merck, Sharp & Dohme, USA 17:30 Adjourn Day Two 18:15 22:30 Off-property Event Transportation will be provided
11 Wednesday, 24 May :30 08:45 Breakfast in the Garden Room Restaurant (Breakfast is included in the CMC Strategy Forum group sleeping room rate; other attendees / guests can pay individually for breakfast if they are not included in the group room rate) 08:30 17:00 Registration in the Muckross Suite Foyer Statistical Tools to Evaluate Quality Attributes for Comparability and Biosimilarity Workshop Session Three in the Muckross Suite Session Chairs: Niklas Ekman, Finnish Medicines Agency and Martin Schiestl, Sandoz Biopharmaceuticals 09:00 09:10 Introduction 09:15 09:40 A Regulatory Statistician s View on Statistical Approaches for Comparability Assessment: Experiences and Future Perspectives Andreas Brandt, BfArM-Federal Institute for Drugs and Medical Devices, Germany 09:40 10:05 Practical Considerations for the Comparative Assessment of Quality Attributes Thomas Stangler, Sandoz Biopharmaceuticals, Austria 10:05 10:30 Criteria for Comparability Martijn van der Plas, CBG-MEB, Netherlands 10:30 10:55 Applying Scientific Considerations and Statistical Approaches in Analytical Similarity Assessment Jennifer Liu, Amgen Inc., USA 11:00 11:30 Networking Break in the Forum Foyer, Level 1 11:30 12:30 Panel Discussion Questions and Answers Andreas Brandt, BfArM, Germany Beverly Ingram, Pfizer Ireland Pharmaceuticals, Ireland Jennifer Liu, Amgen Inc., USA Thomas Stangler, Sandoz Biopharmaceuticals, Austria Peter Stjärnkvist, Medical Products Agency (MPA), Sweden Martijn van der Plas, CBG-MEB, Netherlands 12:30 14:00 Buffet Lunch in the Garden Room Restaurant
12 Wednesday, 24 May continued Opportunities and Obstacles for Accelerated CMC Development Workshop Session Four in the Muckross Suite Session Chairs: Chana Fuchs, CDER, FDA and Jason Hampson, Amgen Inc. 14:00 14:10 Introduction 14:15 14:40 Opportunities for Accelerated Cell Line Development Christopher Frye, Eli Lilly and Company, USA 14:40 15:05 Risk-based Speed: Approaches for Fast to FIH and Right First Time Commercialization Rachel Dinges, Bristol-Myers Squibb Company, USA 15:05 15:30 Registration Enabling Campaign for Accelerated Development: A PPQ Strategy with Minimal Early Investments to Enable Fast to Market Development for a Promising Monoclonal Antibody John Eschelbach, Genentech, a Member of the Roche Group, USA 15:30 15:55 A Holistic Regulatory Approach to Accelerated CMC Development Seán Barry, Health Products Regulatory Authority (HPRA), Ireland 16:00 16:30 Networking Break in the Muckross Suite Foyer 16:30 17:30 Panel Discussion Questions and Answers Seán Barry, Health Products Regulatory Authority (HPRA), Ireland Brigitte Brake, BfArM-Federal Institute for Drugs and Medical Devices, Germany Rachel Dinges, Bristol-Myers Squibb Company, USA John Eschelbach, Genentech, a Member of the Roche Group, USA Christopher Frye, Eli Lilly and Company, USA Trent Munro, Amgen Inc., USA 17:30 17:45 Closing Remarks and Invitation to CMC Strategy Forum Europe 2018 Kowid Ho, F. Hoffmann-La Roche Ltd. 17:45 Adjournment
13 EBE Satellite Session
Welcome to the CMC Strategy Forum Europe 2016
Welcome to the CMC Strategy Forum Europe 2016 The 10 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationWelcome to the CMC Strategy Forum Europe 2016
Welcome to the CMC Strategy Forum Europe 2016 The 10 th annual CMC Strategy Forum Europe, organized by CASSS, will explore a number of critical topics focused on improving the quality in development and
More informationWelcome to the CMC Strategy Forum Europe 2015 Improving Biopharmaceutical Product Quality: Moving Implementation Forward
Welcome to the CMC Strategy Forum Europe 2015 Improving Biopharmaceutical Product Quality: Moving Implementation Forward The ninth annual CMC Strategy Forum Europe, organized by CASSS - An International
More informationWelcome to the CMC Strategy Forum Europe 2018
Welcome to the CMC Strategy Forum Europe 2018 The 12 th annual CMC Strategy Forum Europe, organized by CASSS, will explore many critical topics focused on improving the quality in development and manufacturing
More informationWelcome to the CMC Strategy Forum Europe 2018
Welcome to the CMC Strategy Forum Europe 2018 The 12 th annual CMC Strategy Forum Europe, organized by CASSS, will explore many critical topics focused on improving the quality in development and manufacturing
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to CMC Strategy Forum Japan 2015
Welcome to CMC Strategy Forum 2015 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting of
More informationWelcome to CMC Strategy Forum Japan 2017
Welcome to CMC Strategy Forum Japan 2017 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting
More informationWelcome to. January 26, The Mayflower Hotel Washington, DC USA
Welcome to January 26, 2015 The Mayflower Hotel Washington, DC USA Mission Statement Provide a venue for biotechnology/biological product discussion that focuses on relevant CMC issues throughout the lifecycle
More informationWelcome to the CMC Strategy Forum Europe 2010: Challenges Facing Biopharmaceutical Development in the Next Decade
Welcome to the CMC Strategy Forum Europe 2010: Challenges Facing Biopharmaceutical Development in the Next Decade The fourth annual CMC Strategy Forum Europe, organized by CASSS, An International Separation
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing
Welcome to the CMC Strategy Forum Prior Knowledge: Learning from Our Successes and Failures to Improve Product Development and Manufacturing We are pleased to welcome you to the CMC Strategy Forum. The
More informationWelcome to. January 27, Renaissance Mayflower Hotel Washington, DC USA
Welcome to January 27, 2014 Renaissance Mayflower Hotel Washington, DC USA What is CASSS? MISSION: What We Do CASSS is the global premier, non-profit scientific society facilitating the interaction among
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development
Welcome to the CMC Strategy Forum Phase-appropriate Method Validation Strategies: Policies and Practices to Support Clinical Development We are pleased to welcome you to the CMC Strategy Forum. The purpose
More informationWelcome to CMC Strategy Forum Japan 2018
Welcome to CMC Strategy Forum Japan 2018 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting
More informationWelcome to the CMC Strategy Forum Latin America 2015
Welcome to the CMC Strategy Forum Latin America 2015 On behalf of the CMC Strategy Forum Global Steering Committee and the CMC Strategy Forum Latin America Scientific Program Committee, we would like to
More informationWelcome to the CMC Strategy Forum Europe 2018
Welcome to the CMC Strategy Forum Europe 2018 The 12 th annual CMC Strategy Forum Europe, organized by CASSS, will explore many critical topics focused on improving the quality in development and manufacturing
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to December Hotel Okura Tokyo, Japan
Welcome to 9 10 December 2013 Hotel Okura Tokyo, Japan What is CASSS? Non-profit professional membership society that provides networking and peer-to-peer learning opportunities for professionals involved
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to. April 4-5, DoubleTree by Hilton Hotel Silver Spring, MD USA
Welcome to April 4-5, 2016 DoubleTree by Hilton Hotel Silver Spring, MD USA What is CASSS? Practical Applications of Mass Spectrometry EUROPE JAPAN NORTH AMERICA SOUTH AMERICA CASSS is the leading non-profit
More informationWelcome to the WCBP CMC Strategy Forum
Welcome to the WCBP CMC Strategy Forum We are pleased to welcome you to the 24 th WCBP CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product
More informationWelcome to the CMC Strategy Forum Europe 2014 Improving Biopharmaceutical Product Quality: Moving Implementation Forward
Welcome to the CMC Strategy Forum Europe 2014 Improving Biopharmaceutical Product Quality: Moving Implementation Forward The eighth annual CMC Strategy Forum Europe, organized by CASSS - An International
More informationAGENDA: Joint BWP/QWP workshop with stakeholders in relation to prior knowledge and its use in regulatory applications
22 November 2017 EMA/CHMP/BWP/149179/2017 Human Medicines Research and Development Support Division AGENDA: Joint BWP/QWP workshop with stakeholders in relation to prior knowledge and its use 23 November
More informationWelcome to CMC Strategy Forum Latin America 2017
Welcome to CMC Strategy Forum Latin America 2017 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the fourth
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to CMC Strategy Forum Latin America 2016
Welcome to CMC Strategy Forum Latin America 2016 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the third
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationCMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013
CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions
More informationAnalytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2016)
Analytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2016) Symposium Co-Chairs: Cari Sänger - van de Griend, Kantisto
More informationWelcome to the CMC Strategy Forum (July 20-21, 2016)
Welcome to the CMC Strategy Forum (July 20-21, 2016) We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product
More informationWelcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The
More informationWelcome to CMC Strategy Forum Japan 2018
Welcome to CMC Strategy Forum Japan 2018 On behalf of the CASSS Board of Directors and the CMC Strategy Forum Global Steering Committee, we would like to extend to you a warm welcome to the second meeting
More informationWelcome to the CMC Strategy Forum Europe 2009: CMC Perspectives on Biological Investigational Medicinal Products in Clinical Trials
Welcome to the CMC Strategy Forum Europe 2009: CMC Perspectives on Biological Investigational Medicinal Products in Clinical Trials The organizers of the CMC Strategy Forum Europe, sponsored by CASSS,
More information7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018)
7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018) Symposium Co-Chairs: Guodong Chen, Bristol-Myers Squibb Company David Keire, CDER, FDA April 9-11, 2018 Omni Providence
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationAccelerated Product Development
B i o P r o c e s s EXECUTIVE Accelerated Product Development Leveraging Industry and Regulator Knowledge to Bring Products to Patients Quickly Anthony Mire-Sluis, Michelle Frazier, Kimberly May, Emanuela
More information9:15 Keynote: Regulatory Perspective on Prior Knowledge Martijn van der Plas, Medicines Evaluation Board
Tuesday, 27 November 2018 16 Nov 2018 9:00 Welcome: Opening Remarks & Introductions Falk Klar, PDA Europe Michael De Felippis, Eli Lilly,, 9:15 Keynote: Regulatory Perspective on Prior Knowledge Session
More informationConcept Paper Consideration for setting Specification
CASSS CMC Strategy Forum EBE Satellite Session Concept Paper Consideration for setting Specification 23 rd April 2012, Berlin, Germany Christoph Lindenthal on behalf of the concept paper focus group Development
More informationWelcome to the CMC Strategy Forum Next Generation Biotechnology Product Development, Manufacturing and Control Strategies
Welcome to the CMC Strategy Forum Next Generation Biotechnology Product Development, Manufacturing and Control Strategies We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC
More informationExpert workshop on process validation for the manufacture of biotechnology-derived active substances
9 April 2013 EMA/169648/2012 Human Medicines Development and Evaluation Expert workshop on process validation for the manufacture of biotechnology-derived active substances Final programme 9 April 2013
More informationDRAFT DOCUMENT FINAL COPY TO REFLECT CONFIRMED. Embed Innovations to Transform Your R&D Procurement Model and. Drive Scientific Activities Efficiency
Embed Innovations to Transform Your R&D Procurement Model and Drive Scientific Activities Efficiency April 30 May 1, 2018 Boston, US This conference exceeded all of my expectations. The topics, speakers
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationCLINICAL TRIALS IN RUSSIA
RESEARCH REPORT CLINICAL TRIALS IN RUSSIA SUMMER 2018 RESEARCH GROUP WWW.SRGCRO.COM FOREWORD The Orange Paper is a free publication produced by Synergy Research Group for the pharmaceutical industry since
More information14th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2017)
14th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2017) Symposium Co-Chairs: Michael Boyne, BioTechLogic, Inc. Eef Dirksen, Synthon Biopharmaceuticals
More informationFrance Pharma RepTrak 2017
France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company
More informationPost-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool
Post-approval Change Management Protocols - Current Status and Next Steps on the Way towards a Global Tool Dr. Markus Goese Lead EU CMC Regulatory Policy F. Hoffmann-La Roche Ltd, Basel - Switzerland Presentation
More informationNortheast Regional Forum
Northeast Regional Forum Accelerated CMC Development Wyndham Boston Beacon Hill 5 Blossom Street Boston, MA 02114 Monday, October 8, 2018 Forum Co-chairs: Francis Poulin, Sanofi Bernice Yeung, Shire Pharmaceuticals
More information12th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2015)
12th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (Mass Spec 2015) Symposium Co-Chairs: Steven Cohen, Northeastern University Christopher Yu, Genentech, a
More informationPRELIMINARY PROGRAM Bay Area Discussion Group
PRELIMINARY PROGRAM Bay Area Discussion Group Co-chairs: Min Chen, Ultragenyx Pharmaceutical Vinaya Kapoor, Janssen, Pharmaceutical Companies of Johnson & Johnson South San Francisco Conference Center
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) Feedback from 147 Nordic patient groups PUBLISHED JUNE 2016 Syöpälääkkeiden kehitys on ollut hyvä, ja yhä useammat paranevat.
More information8 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2019)
8 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2019) Symposium Co-Chairs: Katherine Bowers, FUJIFILM Diosynth Biotechnologies Guodong Chen, Bristol-Myers Squibb Company
More information4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015)
4 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2015) Symposium Co-chairs: Jamie Moore, Genentech, a Member of the Roche Group Linda Narhi, Amgen Inc. April 13-15, 2015
More informationCASSS CMC Strategy Forum EU Introduction to EBE Satellite Session
CASSS CMC Strategy Forum EU 2015 - Introduction to EBE Satellite Session Copenhagen - May 4, 2015 Dr. Markus Goese, Lead EU CMC Regulatory Policy F. Hoffmann - La Roche Ltd, Basel FROM SORRENTO TO COPENHAGEN:
More informationWorkshop with stakeholders on support to quality development in early access approaches (i.e. PRIME, Breakthrough Therapies)
20 November 2018 EMA/493240/2018 Human Medicines Research and Development Support Division Workshop with stakeholders on support to quality development in early access approaches (i.e. PRIME, Breakthrough
More information7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018)
7 th International Symposium on Higher Order Structure of Protein Therapeutics (HOS 2018) Symposium Co-Chairs: Guodong Chen, Bristol-Myers Squibb Company David Keire, CDER, FDA April 9-11, 2018 Omni Providence
More informationLSE Health Market Access Academy April 2018, London September 2018, London
LSE Health Market Access Academy 9 13 April 2018, London 10 14 September 2018, London In cooperation with the Boston Consulting Group Market Access Roundtable LSE Health Market Access Academy 2 The London
More informationTuesday, February 21, :15 a.m. 5:30 p.m. Registration Open. 8:15 a.m. 8:30 a.m. Continental Breakfast
2017 PDA Pharmaceutical Quality Metrics and Quality Culture Conference February 21 22, 2017 Bethesda North Marriott Hotel & Conference Center Bethesda, MD As of January 30, 2017 Tuesday, February 21, 2017
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence Wassim Nashabeh Global Head Pharma Technical Regulatory Policy F. Hoffmann-La Roche, Basel, Switzerland CMC Strategy
More information3rd Annual Global Drug Bioavailability Enhancement Summit
3rd Annual Global Drug Bioavailability Enhancement Summit Event Summary Most drugs on today s market display poor solubility, but the use of modern solubilization technologies can improve a drug product
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationThe first CMC Strategy Forum
B i op r o c e s s Technical Quality by Design: The Next Phase Potential Regulatory Implications and Filing of QbD Data Anthony Mire-Sluis, Mark Schenerman, Rohin Mhatre, Siddharth Advant, John Dougherty,
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationWorkshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions
Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions Sponsored by the HESI Immunotoxicology Technical Committee Silver Spring, MD 22 October 2013 Objectives of the
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationAnalytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2015)
Analytical Technologies Europe: Symposium on the Practical Applications including CE, LC and MS in the Biopharmaceutical Industry (AT Europe 2015) Symposium Co-Chairs: Cari Sänger - van de Griend, Kantisto
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016 Dans notre domaine de maladies rares où des efforts ont été faits pour
More informationParadigm Change in Manufacturing Operations
Technical Report No. 56 (Revised 2016) Application of Phase-Appropriate Quality System and cgmp to the Development of Therapeutic Protein Drug Substance (API or Biological Active Substance) Paradigm Change
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) Feedback from 797 patient groups in Europe PUBLISHED APRIL 2016 The perception [of pharma] has changed in the last years,
More informationSponsorship & Branding opportunities
Learn. Connect. Optimize. Tuesday, June 26, 2018 Hyatt regency Hotel, New Brunswick, New Jersey education Forums networking keynote speaker Sponsorship & Branding opportunities Limited Sponsorships available!
More informationImmunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
More informationAs defined in the US Code of
Technical B i op r o c e s s The Roles of Bioactivity Assays in Lot Release and Stability Testing by Noel Rieder, Hélène Gazzano-Santoro, Mark Schenerman, Robert Strause, Chana Fuchs, and Anthony Mire-Sluis,
More informationRegulatory Information Management
Regulatory Information Management Hotel Meliá Avenida América, Madrid http://www.reginfomanagement.com/ Day 1 - Tuesday 26 April 2016 08:30-09:00 Conference Registration 09:00-09:10 Opening remarks from
More informationAn Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More informationInnovation for Pharma to engage with the mobile user.
www.healthnetworkcommunications.com/mobile Innovation for Pharma to engage with the mobile user 24-27 April 2012 Sheraton Hotel, Amsterdam, The Netherlands created by sponsor endorsed by Smart phones and
More informationUSP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure
USP Packing General Chapters , , : An Industry Perspective on Elemental Impurities Compliance for Container/Closure Tim Shelbourn Co-chair, IQ Consortium ICH Q3D Compliance Working Group
More informationPharmacopoeia 2019 PDA EUROPE. The 2 nd Annual PDA Conference on International Developments in the Pharmacopoeial Landscape PEOPLE SCIENCE AND
pda.org/eu/pharma2019 2019 PDA EUROPE Pharmacopoeia The 2 nd Annual PDA Conference on International Developments in the Pharmacopoeial Landscape CONNECTING PEOPLE SCIENCE AND REGULATION 16-17 MAY 2019
More informationThe State of QbD in the Biopharmaceutical Industry Conference
The State of QbD in the Biopharmaceutical Industry Conference Criticality Assessment, Design Space Implementation and Control 10 11 April 2013 Sheraton Fisherman s Wharf San Francisco, California USA Sponsored
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationTime Efficiencies to Be Gained from Platform Approaches to Drug Development
Time Efficiencies to Be Gained from Platform Approaches to Drug Development Monday, July 27th, 2015 Room 100 National Academy of Sciences Keck Center 500 5 th Street NW, Washington DC 20001 Meeting Description
More informationTheme Sub-theme Quote / issue. Inconsistency and
Theme Sub-theme Quote / issue Inconsistency and ambiguity Problematic and contradictory use of the term "all". Abbvie's webpage describing their transparency policy says "AbbVie will submit a manuscript
More informationDose-finding of Small Molecule Oncology Drugs
Dose-finding of Small Molecule Oncology Drugs May 18-19, 2015 Washington Court Hotel, Washington, DC This workshop will provide a forum for discussion of the best practices on dose finding of small molecule
More informationDose-finding of Small Molecule Oncology Drugs
Dose-finding of Small Molecule Oncology Drugs May 18-19, 2015 Washington Court Hotel, Washington, DC This workshop will provide a forum for discussion of the best practices on dose finding of small molecule
More informationCASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011
CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise
More informationINDUSTRY PERSPECTIVE ON THE CONTROL OF VISIBLE PARTICLES
INDUSTRY PERSPECTIVE ON THE CONTROL OF VISIBLE PARTICLES Tapan Das Biologics Development, Bristol-Myers Squibb European Biopharmaceutical Enterprises (EBE) satellite Session CMC Strategy Forum Europe 2017,
More informationDISSOLUTION AND TRANSLATIONAL MODELING STRATEGIES ENABLING PATIENT-CENTRIC PRODUCT DEVELOPMENT
THE UNIVERSITY OF MARYLAND CENTER FOR EXCELLENCE IN REGULATORY SCIENCE AND INNOVATION AND THE FOOD AND DRUG ADMINISTRATION PRESENT: DISSOLUTION AND TRANSLATIONAL MODELING STRATEGIES ENABLING PATIENT-CENTRIC
More informationEvaluate Data Kit Pharma, Biotech and Medtech, May 2018
Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales
More informationExplore Ways to Enhance Collaboration Between Key Players
Joint EFGCP / DIA / EMA Better Medicines for Children Conference 2014 on Explore Ways to Enhance Collaboration Between Key Players 30 th September & 1 st October 2014 EMA, London, United Kingdom Organised
More informationThe TOPRA 40 th Spring Introductory Course: Introduction to Pharmaceutical Regulatory Affairs. Module 0 of the MSc Regulatory Affairs
The TOPRA 40 th Spring Introductory Course: Introduction to Pharmaceutical Regulatory Affairs Module 0 of the MSc Regulatory Affairs 16 th to 19 th April 2018 Coppid Beech Hotel, John Nike Way, Bracknell,
More informationEBE s Approach to Development of Concept, Position & Reflection Papers. Saroj Ramdas, GSK on behalf of EBE Biomanufacturing Working Group
EBE s Approach to Development of Concept, Position & Reflection Papers Saroj Ramdas, GSK on behalf of EBE Biomanufacturing Working Group Overview Definitions of EBE papers How do we develop papers? Published
More informationAsia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation
Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation Henry Li, General Counsel, RDPAC Beijing, China About RDPAC: R&D based Pharmaceutical Association
More information4th PQRI/FDA Conference on Advancing Product Quality: Patient-Centric Product Design, Drug Development, and Manufacturing
4th FDA/PQRI Conference on Advancing Product Quality DRAFT August 6, 2018 April 9-11, 2019 CONFERENCE AT-A-GLANCE 4th PQRI/FDA Conference on Advancing Product Quality: Patient-Centric Product Design, Drug
More informationScience of Stability
IT S ALL ABOUT THE SCIENCE Science of Stability 3rd Annual Conference 2017 3 rd - 5 th Ocber Crowne Plaza Hotel - Blanchardswn Dublin, Ireland science of stability 3rd annual conference 2017 sponsors science
More information4th PQRI/FDA Conference on Advancing Product Quality: Patient-Centric Product Design, Drug Development, and Manufacturing
4th FDA/PQRI Conference on Advancing Product Quality DRAFT August 6, 2018 April 9-11, 2019 CONFERENCE AT-A-GLANCE 4th PQRI/FDA Conference on Advancing Product Quality: Patient-Centric Product Design, Drug
More informationCode of Conduct Interfarma Review 2012
Code of Conduct Interfarma Review 2012 Segundo Congreso Latinoamericano de Compliance de la Industria Farmacéutica e Insumos para la Salud, y el Foro de Buenas Prácticas Interfarma has a cooperation agreement
More informationCorporate Reputation of Pharma in 2017 the Patient Perspective
PRESS RELEASE: 'Corporate Reputation of Pharma in - the Global Patient Perspective' Corporate Reputation of Pharma in the Patient Perspective EMBARGOED PRESS RELEASE: 6AM GMT, THURSDAY, APRIL 5TH 2018
More informationInternational Regulatory Forum of Human Cell Therapy and Gene therapy Products
PROGRAM International Regulatory Forum of Human Cell Therapy and Gene therapy Products March 16th, 2016 Osaka International Convention Center, Osaka, Japan Organized by Pharmaceuticals and Medical Devices
More information